Yield10 Bioscience, Inc. (YTEN) Reports Q2 Loss of $0.96/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
Yield10 Bioscience Announces Second Quarter 2017 Financial Results
August 10, 2017 4:05 PM EDTWOBURN, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN) today reported financial results for the three months ended June 30, 2017.
We made solid progress in the second quarter driving toward the generation of proof points in our research and development programs, commented Oliver Peoples, Ph.D., President and Chief Executive Officer. We announced the start of field tests at sites in Canada in early June for the evaluation of our novel yield trait gene C3003 in Camelina and canola. Harvest of the crops is expected to start in the... More



